Biogen (BSP:BIIB34) Change In Inventory : R$-1,160 Mil (TTM As of Mar. 2024)

View and export this data going back to 2016. Start your Free Trial

What is Biogen Change In Inventory?

Biogen's change in inventory for the quarter that ended in Mar. 2024 was R$-387 Mil. It means Biogen's inventory increased by R$387 Mil from Dec. 2023 to Mar. 2024 .

Biogen's change in inventory for the fiscal year that ended in Dec. 2023 was R$-641 Mil. It means Biogen's inventory increased by R$641 Mil from Dec. 2022 to Dec. 2023 .

Biogen's Total Inventories for the quarter that ended in Mar. 2024 was R$12,533 Mil.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory. Biogen's Days Inventory for the quarter that ended in Mar. 2024 was 421.04.

Inventory Turnover measures how fast the company turns over its inventory within a year. Biogen's Inventory Turnover for the quarter that ended in Mar. 2024 was 0.22.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Biogen's Inventory-to-Revenue for the quarter that ended in Mar. 2024 was 1.09.

Biogen Change In Inventory Historical Data

The historical data trend for Biogen's Change In Inventory can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biogen Change In Inventory Chart

Biogen Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Inventory

Get a 7-Day Free Trial

-78.81

-1,627.27

-2,614.83

-1,679.58

-641.38

Biogen Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Change In Inventory	Get a 7-Day Free Trial															145.32	-451.39	149.15	-470.38	-386.93

Biogen Change In Inventory Calculation

Change In Inventory is the difference between last period's ending inventory and the current period's ending inventory.

Change In Inventory for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was R$-1,160 Mil.

Biogen (BSP:BIIB34) Change In Inventory Explanation

1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Biogen's Days Inventory for the quarter that ended in is calculated as:

Days Inventory	=	Average Total Inventories	/	Cost of Goods Sold	*	Days in Period
	=	12458.458	/	2700.048	*	365 / 4
	=	421.04

2. Inventory Turnover measures how fast the company turns over its inventory within a year.

Biogen's Inventory Turnover for the quarter that ended in Mar. 2024 is calculated as

Inventory Turnover	=	Cost of Goods Sold	/	Average Total Inventories
	=	2700.048	/	12458.458
	=	0.22

3. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Biogen's Inventory to Revenue for the quarter that ended in Mar. 2024 is calculated as

Inventory-to-Revenue	=	Average Total Inventories	/	Revenue
	=	12458.458	/	11406.232
	=	1.09

Biogen Change In Inventory Related Terms

Thank you for viewing the detailed overview of Biogen's Change In Inventory provided by GuruFocus.com. Please click on the following links to see related term pages.

Biogen (BSP:BIIB34) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Biogen Inc (BSP:BIIB34) » Definitions » Change In Inventory

Comparable Companies

Traded in Other Exchanges

BIIB:USA BIIB:Mexico 1BIIB:Italy IDP:Germany BIIB:Austria BIIB:Argentina

Address

225 Binney Street, Cambridge, MA, USA, 02142

Website

https://www.biogen.com

Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel multiple sclerosis drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is copromoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with Sobi) were spun off as part of Bioverativ in 2017. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (post-partum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology-related fields.

Biogen (BSP:BIIB34) Headlines

No Headlines